Katsuki Muramoto

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features.

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features.

Journal: The Prostate

Published: December 11, 2025

Impact of preoperative urine culture on postoperative febrile urinary tract infection after ureterorenoscopic lithotripsy.

Impact of preoperative urine culture on postoperative febrile urinary tract infection after ureterorenoscopic lithotripsy.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: October 31, 2025

Real-World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer.

Real-World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: July 10, 2025

Achieving Complete Response in Metastatic Prostate Cancer With Triplet Therapy and Local Radiation: A Case Report.

Achieving Complete Response in Metastatic Prostate Cancer With Triplet Therapy and Local Radiation: A Case Report.

Journal: Cureus

Published: May 16, 2025

Complete Response Case of Metastatic Hormone-Sensitive Prostate Cancer Treated With Triplet Therapy (Androgen Deprivation Therapy + Docetaxel + Darolutamide).

Complete Response Case of Metastatic Hormone-Sensitive Prostate Cancer Treated With Triplet Therapy (Androgen Deprivation Therapy + Docetaxel + Darolutamide).

Journal: Cureus

Published: March 26, 2025

Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study.

Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study.

Journal: Japanese journal of clinical oncology

Published: February 27, 2025

Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort.

Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort.

Journal: The Prostate

Published: January 31, 2025

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Journal: The Prostate

Published: December 19, 2024

A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma.

A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma.

Journal: International cancer conference journal

Published: December 15, 2024

Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.

Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.

Journal: Clinical genitourinary cancer

Published: December 05, 2024

Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter study.

Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter study.

Journal: Urologic oncology

Published: August 09, 2024

Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter study.

Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter study.

Journal: Urologic oncology

Published: July 27, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026